Binding of humanized or chimeric mAbs on B-cell lines
. | Geometric mean fluorescence . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | None . | Anti-CEA: hMN14 . | Anti-CD74: hLL1 . | Anti-CD22: hLL2 . | Anti-CD20: hA20 . | Anti-CD20: rituximab . | Anti-HLA-DR: hL243γ4P . | ||||||
| Daudi | 3.2 | 3.2 | 48.8 | 51.7 | 241.0 | 380.5 | 937.4 | ||||||
| Namalwa | 2.6 | 2.4 | 7.8 | 6.4 | 10.1 | 14.1 | 260.9 | ||||||
| Raji | 6.9 | 7.0 | 95.1 | 22.6 | 267.1 | 394.6 | 972.0 | ||||||
| Ramos | 3.1 | 3.1 | 23.3 | 14.6 | 203.7 | 375.0 | 277.6 | ||||||
| RL | 2.4 | 2.8 | 7.9 | 5.1 | 127.5 | 147.8 | 112.2 | ||||||
| SU-DHL-6 | 4.6 | 4.9 | 17.3 | 11.0 | 1199.3 | 1308.9 | 572.3 | ||||||
| FSCCL | 2.7 | 2.7 | 8.7 | 4.2 | 8.9 | 12.5 | 466.8 | ||||||
. | Geometric mean fluorescence . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | None . | Anti-CEA: hMN14 . | Anti-CD74: hLL1 . | Anti-CD22: hLL2 . | Anti-CD20: hA20 . | Anti-CD20: rituximab . | Anti-HLA-DR: hL243γ4P . | ||||||
| Daudi | 3.2 | 3.2 | 48.8 | 51.7 | 241.0 | 380.5 | 937.4 | ||||||
| Namalwa | 2.6 | 2.4 | 7.8 | 6.4 | 10.1 | 14.1 | 260.9 | ||||||
| Raji | 6.9 | 7.0 | 95.1 | 22.6 | 267.1 | 394.6 | 972.0 | ||||||
| Ramos | 3.1 | 3.1 | 23.3 | 14.6 | 203.7 | 375.0 | 277.6 | ||||||
| RL | 2.4 | 2.8 | 7.9 | 5.1 | 127.5 | 147.8 | 112.2 | ||||||
| SU-DHL-6 | 4.6 | 4.9 | 17.3 | 11.0 | 1199.3 | 1308.9 | 572.3 | ||||||
| FSCCL | 2.7 | 2.7 | 8.7 | 4.2 | 8.9 | 12.5 | 466.8 | ||||||
An indirect flow cytometry assay was performed using FITC-GAH Fc-specific second antibody staining